Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zeneca, Inc. history
Zeneca, Inc. company history timeline
Xylocaine remained one of Astra's most popular products for years: by 1984, local anesthetics constituted 24 percent of Astra's total group sales and Xylocaine alone contributed SKr696 million.
The development of several new drugs to treat viral infections, gastrointestinal agents, and the central nervous system helped propel Astra's pre-tax earnings over the one billion kroner mark in 1985.
Sales of the asthma drug Pulmicort helped propel total revenues to over SKr6.2 billion in 1988, by which time pre-tax earnings had risen to SKr1.5 billion.
In 1988, they hired an unlikely candidate: 44-year-old chocolatier Hanakan Mogren.
Mogren more than doubled the sales force from about 3,000 in 1990 to nearly 7,000 by mid-decade and boosted the company's roster of subsidiaries to 40 nations worldwide.
The Formation of Zeneca in 1993
In 1995, the company suffered from an embarrassing scandal when Lars Bildman, head of Astra's North American operations was fired and faced criminal charges for defrauding the company of over US$1 million.
In 1995, ZPS developed fruits that stay firmer longer, thus reducing wastage for farmers since more of the crop is ripened at one time.
By the end of fiscal 1996, Zeneca reported sales of £5.4 billion and a profit of more than £1 billion for the first time in its history.
1996: Astra's Losec becomes world's best-selling prescription drug.
Actelion profile and corporate video Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.
Beginning in 1997, the company's shares began to underperform compared to the rest of the industry.
In 1997, the company was the second largest seller of cancer drugs.
Finally, in December of 1998, the company announced its impending merger with Astra, who had recently disentangled itself from its obligations to Merck.
The company merged its agrochemical business with that of Novartis (another drug company) in 2000.
Once Losec's patent expired in 2001, other companies would be able to produce it generically at a significantly lowered price.
APIL had since 2010 been associated with BMS in promotions of Onglyza (Saxagliptin) Kombiglyze XR (Saxagliptin and Metformin HCl extended release) and Byetta in the Indian Pharmaceutical Market.
The National Pharmaceutical Pricing Policy 2012 announced by the Government in December 2012 had brought 348 medicines covered in the National List of Essential Medicines (NLEM) under price control.
Neither the company nor any of its officials/employees have been named as accused in the charge sheet.In December 2013 AstraZeneca globally announced an agreement to purchase Bristol Myers-Squibb' (BMS) 50% interest in AstraZeneca's and BMS's joint diabetes business.
The establishment programme was delivered to plan with planned QC transfers and the majority of tablet transfers delivered by the end of the Financial Year 2013-14.
The Year 2013-14 witnessed a series of regulatory interventions in the Indian Pharmaceutical Market.
In 2015-16 Meronem became the company's first brand to cross the Rs.
At 1.79 million, demat accounts opened in June fewest since Feb 2021
Rate Zeneca, Inc.'s efforts to communicate its history to employees.
Zeneca, Inc. jobs
Do you work at Zeneca, Inc.?
Is Zeneca, Inc.'s vision a big part of strategic planning?
Zeneca, Inc. competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cephalon | 1987 | $2.8B | 3,726 | - |
| ECR International | 1928 | $107.2M | 500 | - |
| Big Ass Fans | 1999 | $32.0M | 699 | 31 |
| Leica Biosystems Richmond Inc | 1977 | $1.4M | 6 | - |
| Hill's Pet Nutrition | 2015 | $2.2B | 750 | - |
| KARL STORZ Endoscopy | 1945 | $500.0M | 2,127 | 25 |
| George Delallo Company | - | $300.0M | 200 | - |
| Nobel Biocare | 1981 | $57.0M | 500 | - |
| Dynatron | 1991 | $7.5M | 20 | - |
Zeneca, Inc. history FAQs
Zippia gives an in-depth look into the details of Zeneca, Inc., including salaries, political affiliations, employee data, and more, in order to inform job seekers about Zeneca, Inc.. The employee data is based on information from people who have self-reported their past or current employments at Zeneca, Inc.. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Zeneca, Inc.. The data presented on this page does not represent the view of Zeneca, Inc. and its employees or that of Zippia.
Zeneca, Inc. may also be known as or be related to Zeneca, Zeneca Inc and Zeneca, Inc.